IL22 and inflammation: IL-22, the crucial Th22 signature cytokine, its role had been demonstrated by developing literatures, which reported that neutralization or genetic deletion of IL-22 could alleviate or exacerbate the severity of kinds diseases such as antigen-induced airway inflammation and T cell-mediated hepatitis [17,18], indicating that targeting IL-22 might represent a promising novel therapeutic approach for acute-phase response, immunity and inflammation.